Cargando…

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

BACKGROUND: Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). METHODS: We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxyge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldman, Jason D., Lye, David C.B., Hui, David S., Marks, Kristen M., Bruno, Raffaele, Montejano, Rocio, Spinner, Christoph D., Galli, Massimo, Ahn, Mi-Young, Nahass, Ronald G., Chen, Yao-Shen, SenGupta, Devi, Hyland, Robert H., Osinusi, Anu O., Cao, Huyen, Blair, Christiana, Wei, Xuelian, Gaggar, Anuj, Brainard, Diana M., Towner, William J., Muñoz, Jose, Mullane, Kathleen M., Marty, Francisco M., Tashima, Karen T., Diaz, George, Subramanian, Aruna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377062/ https://www.ncbi.nlm.nih.gov/pubmed/32459919 http://dx.doi.org/10.1056/NEJMoa2015301

Ejemplares similares

72. Remdesivir vs Standard Care in Patients with Moderate covid-19
por: Marty, Francisco M, et al.
Publicado: (2020)

557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients
por: Arribas, Jose Ramon, et al.
Publicado: (2020)

73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir
por: Diaz, George, et al.
Publicado: (2020)

548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19
por: Castagna, Antonella, et al.
Publicado: (2020)

561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19
por: Criner, Gerard J, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
por: Humeniuk, Rita, et al.
Publicado: (2020)

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
por: Humeniuk, Rita, et al.
Publicado: (2021)

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
por: Olender, Susan A, et al.
Publicado: (2021)

Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States
por: Chokkalingam, Anand P., et al.
Publicado: (2022)

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
por: Gottlieb, Robert L., et al.
Publicado: (2021)

Compassionate Use of Remdesivir for Patients with Severe Covid-19
por: Grein, Jonathan, et al.
Publicado: (2020)

Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting
por: Pan, David Z., et al.
Publicado: (2023)

Reply to Yan and Muller, “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”
por: Murakami, Eisuke, et al.
Publicado: (2021)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023)

Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019
por: Burwick, Richard M, et al.
Publicado: (2020)

Remdesivir for the Treatment of Covid-19 — Final Report
por: Beigel, John H., et al.
Publicado: (2020)

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
por: Aleissa, Muneerah M., et al.
Publicado: (2020)

LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Hill, Joshua A, et al.
Publicado: (2021)

Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir
por: Wongboonsin, Janewit, et al.
Publicado: (2021)

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study
por: Brown, Samuel M., et al.
Publicado: (2023)

476. Gilead Sciences’ Commitment to the COVID-19 Pandemic
por: Lee, EunYoung, et al.
Publicado: (2020)

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
por: Olender, Susan A, et al.
Publicado: (2020)

Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned
por: Dölken, Lars, et al.
Publicado: (2021)

Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain
por: Soriano, Alejandro, et al.
Publicado: (2021)

EE410 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Three Countries of LATAM: Argentina, Chile, and Colombia
por: Montejano, R, et al.
Publicado: (2022)

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021)

Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes
por: Chaturvedi, Nimisha, et al.
Publicado: (2019)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

538. Clinical Evaluation of Drug-drug Interactions with Remdesivir
por: Peng, Chi-Chi, et al.
Publicado: (2023)

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
por: Rosas, Ivan O., et al.
Publicado: (2021)

SARS-CoV-2 viral load dynamics in immunocompromised critically ill patients on remdesivir treatment
por: Lahmer, Tobias, et al.
Publicado: (2022)

Remdesivir for patients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2021)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Remdesivir: From Ebola to COVID-19
por: Santoro, M. Gabriella, et al.
Publicado: (2021)

Remdesivir: Infusion site reaction following extravasation of remdesivir: case report
Publicado: (2021)

Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion
por: Maldarelli, Grace A, et al.
Publicado: (2020)

Remdesivir bei Patienten mit COVID-19
por: Augustin, M., et al.
Publicado: (2020)

Identifying Functional Adenovirus-Host Interactions Using Tandem Mass Spectrometry
por: Gaggar, Anuj, et al.
Publicado: (2007)

Remdesivir: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_no43i651lhf8mr4ghrb5u0gr4t